key: cord-0842256-wt1ehikf
authors: Tomasoni, D.; Bai, F.; Castoldi, R.; Barbanotti, D.; Falcinella, C.; Mulè, G.; Mondatore, D.; Tavelli, A.; Vegni, E.; Marchetti, G.; d’Arminio Monforte, A.
title: Anxiety and depression symptoms after virological clearance of COVID‐19: a cross‐sectional study in Milan, Italy
date: 2020-08-25
journal: J Med Virol
DOI: 10.1002/jmv.26459
sha: e3e8888220ddc360f35de9bba106ead3d080eb3c
doc_id: 842256
cord_uid: wt1ehikf

Prevalence of anxiety/depression was investigated in 105 COVID‐19 patients at 1‐3 months from virological clearance by Hospital Anxiety and Depression Scale (HADS‐A/D). 30% of patients displayed pathological HADS‐A/D, 52.4% showed persistent symptoms. Pathological HADS‐A/D patients more commonly reported symptom persistence, even after adjustment for age, gender, disease severity. Psychological assessments should be encouraged in COVID‐19 patients’ follow‐up. This article is protected by copyright. All rights reserved.

An outbreak of novel coronavirus (SARS-CoV-2) has emerged in Northern Italy at the beginning of 2020, following an earlier epidemic in China. The infection may result in a severe systemic disease affecting a number of organs, first of all lungs. Thus, it is crucial to arrange a follow-up of recovered patients in order to early identify possible organ damage and long-term sequelae 1 .

To date, data on follow-up of patients recovered from COVID-19 are missing; the first case series described that symptoms, such as fever, cough and fatigue, could persist after hospital discharge 2 . In addition to multiorgan impairment, possible psychological consequences need to be addressed 1 . Recently, a nationwide survey among Italian population showed that a high proportion of people suffered from anxiety and depression This article is protected by copyright. All rights reserved.

Accepted Article during the epidemics 3 , even if not affected by COVID-19 disease. Preliminary data suggest that anxiety and depression might also persist in patients recovering from COVID-19 4 . Psychological distress is therefore an important concern for COVID-19 patients and should not be neglected during hospitalization and follow-up. In this context, we aimed to investigate prevalence and possible predictors of anxiety anddepression after clinical and virological recovery from COVID-19 disease. Methods One to three months after virological clearance patients underwent a medical examination including: persistence or resolution of physical symptoms (fever, gastrointestinal symptoms, at rest and exertional dyspnea, asthenia, anosmia/dysgeusia, pain, cognitive deficits defined as memory disorders, vital signs and peripheral oxygen saturation). Patients also completed the Hospital Anxiety and Depression Scale (HADS) questionnaire to investigate psychological symptoms (anxiety and depression): a score ≥8 for anxiety and depression was considered as borderline/pathological. Lastly, the presence of cognitive disorders in patients over 65 years was evaluated by Mini Mental State Examination (MMSE, a corrected score of ≤25 was considered pathological 5 ).

Symptom persistence was defined as the reported persistence of at least one physical symptom among those investigated. All data were recorded on an electronic case report This article is protected by copyright. All rights reserved.

form. Mann-Whitney test, Chi-square test or Fisher's Exact test were used for statistics, as appropriate; correction for confounders was made by multivariable logistic regression analysis.

A total of 105 patients were enrolled; patients' characteristics are shown in Table I: 73% were male, median age was 55 years (IQR 43-65). All patients displayed interstitial pneumonia at hospital admission. As regards disease severity during the acute phase, 72.4% of subjects needed low-flow oxygen or no oxygen therapy, while 27.6% required continuous positive airway pressure systems, non-invasive mechanical ventilation or orotracheal intubation (Table I) .

Only 6/105 (5.7%) and 3/105 (2.8%) patients were being treated with antidepressant and anxiolytic therapies before admission, respectively. Patients underwent medical examination a median of 46 (IQR 43-48) days after virological clearance.

A total of 100/105 (95.2%) patients completed HADS questionnaire (5 foreigners subjects were not able to complete it for language reasons); anxiety items in HADS (HADS-A) were abnormal in 29/100 (29%) patients, while depression items (HADS-D) in 11/100 (11%). HADS-A/D (at least one of the two scales) resulted pathological in one third (30/100, 30%) of patients, of which 10/30 (33%) presented both anxiety and depression, 19/30 (63%) had only anxiety and 1/30 (4%) only depression. Patients with pathological HADS-A/D did not differ in demographic and clinical parameters or in disease severity, compared to subjects with a normal HADS-A/D score (Table I) .

Interestingly, more than half of the patients (55/105, 52.4%) reported persistence of physical symptoms at the follow-up visit: patients with abnormal HADS-A/D showed a This article is protected by copyright. All rights reserved.

higher proportion (77% vs 43%, p=0.002) of physical symptoms persistence, compared to subjects displaying normal HADS-A/D (Table I) . Looking at individual symptoms, 31.4% of patients reported ongoing asthenia and 27.6% dyspnea; these symptoms were more commonly reported by patients with pathological HADS-A/D (Table I) .

Finally, 17.1% of patients complained persistent cognitive disorders, once again more frequently in those with altered HADS-A/D (36.7% vs 10%). Among 25 patients who performed MMSE, 10 (40%) patients had scores that were compatible with mild or worst cognitive impairment, without differences between the two groups (Table I ).

In the multivariable logistic regression analysis, the persistence of physical symptoms was confirmed to be independently associated with anxiety and depression (i.e. abnormal HADS-A/D) (AOR 4.51; CI 95%: 1.56-13.05, p=0.006), after adjusting for age, gender and severity of disease. By administering HADS-A/D to subjects clinically and virologically recovered from SARS-CoV-2 pneumonia, we detected a substantial proportion of patients still suffering from anxiety (29%) and depression (11%) symptoms. Moreover, subjects with pathological HADS-A/D scores complained persistence of any physical symptoms more frequently than patients with normal scores. In particular, ongoing asthenia, dyspnea and cognitive deficits were the predominant symptoms. Contrary to our expectations, we did not find any correlation between the severity of disease in the acute phase, and anxiety/depression, possibly due to the limited number of severe cases included in this analysis.

We found 17% of subjects reporting cognitive disorders; direct viral invasion of Central Nervous System or immune responses triggered by the infection may lead to brain damage with subsequent cognitive impairment and psychological distress 10 .

This study has some limitations: (i) only patients with confirmed virological recovery (negative SARS-CoV-2 PCR on respiratory specimens on two consecutive samples after clinical resolution) were included in the study, while it could be interesting to study anxiety/depression symptoms also in subjects with persistent positive PCR after clinical recovery; (ii) sample size is limited, our results need to be confirmed when the follow-up of a larger population will be available; (iii) baseline (pre-COVID-19) psychological evaluation of the study population was not available, so that no causality hypothesis This article is protected by copyright. All rights reserved.

among anxiety or depression and persistence of physical symptoms can be speculated;

(iv) data concerning SARS-CoV-2 infection and outcome in other family members, as well as level of education, a factor known to be positively correlated to anxiety levels, were not available.

In conclusion, a considerable proportion of COVID-19 patients still experienced psychological distress and ongoing physical symptoms after hospital discharge, underlining the complexity of COVID-19 patients management even after clinical and virological recovery, and the need of long-term follow-up within multidisciplinary teams 11 .

The authors declare that they don't have any conflict of interest.

Ovest e Adda Martesana ONLUS. 

Follow-up studies in COVID-19 recovered patients -is it mandatory?

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study

A nationwide survey of psychological distress are presented as median, (Interquartile Range)

Abbreviations: CPAP, Continuous Positive Airway Pressure; OTI, orotracheal intubation; NIV, non-invasive ventilation

b Symptoms' persistence: persistence of at least one symptom among those investigated including fever, gastro-intestinal symptoms, at rest and exertional dyspnea, asthenia, anosmia/dysgeusia, pain, cognitive deficits defined as memory disorders

Other symptoms included: chest pain, headache, constipation, tinnitus, insomnia, palpitations, NSTEMI, cough, sore throat

Mini Mental State Examination (adjusted for age and education years)

We are grateful to all patients and their families for their kind participation in the study.